Clinical Trials Browser

Phase 2 × INDUSTRY × onvansertib × Clear all

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05593328 2025-01-10

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

72 enrolled 21 charts

Metastatic Castration-Resistant Prostate Cancer